Exploratory Clinical Study Looks Into CBD For Blood Pressure Reduction

Lexaria Bioscience Corp. (OTC: LXRP) (CSE:LXX) will launch a clinical study to assess the potential of CBD in blood pressure reduction.

The study will be conducted among volunteers with pre-hypertension or mild hypertension, using CBD formulated using Lexaria’s patented technology, DehydraTECH.

“The primary outcome will be automated measures of blood pressure and heart rate,” the press release states. “Secondary outcome …

Full story available on Benzinga.com

More Exploratory Clinical Study Looks Into CBD For Blood Pressure Reduction